DRUG · Unmapped registry intervention
tadalafil 20 mg then 40 mg if tolerated
Find medicine records ·
Find other trials using this name
Clinical trial
Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary Hypertension
NCT06350773
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedPhosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary Hypertension
Design: INTERVENTIONAL · Status: COMPLETED · Phase: NA
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Group 2 Pulmonary Hypertensionunresolved
CpcPHunresolved
Interventions
Sponsors & collaborators
Beni-Suef Universitylead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06350773 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.